Does Medtech Have an Appetite for M&A?—Boston Scientific

Boston Scientific's Commentary on M&A"Near term, our capital allocation priorities are to prepay debt, manage our contingencies and pursue tuck-in M&A."

May 13, 2016

1 Min Read
Does Medtech Have an Appetite for M&A?—Boston Scientific

Boston Scientific's Commentary on M&A

"Near term, our capital allocation priorities are to prepay debt, manage our contingencies, and pursue tuck-in M&A."

Daniel Brennan, Boston Scientific CFO, according to a Seeking Alpha transcript of the company's first quarter earnings call

[Image courtesy of STUART MILES/FREEDIGITALPHOTOS.NET]  

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like